{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-293959","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.795749+00:00","generated_at":"2026-06-07T13:35:57.059824+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioAtla reports Phase 1 data for BA3071: confirmed responses in solid tumors, safe profile, Phase 2 initiated","bullets":["Phase 1 dose-escalation of BA3071 (CAB-CTLA-4) in 18 PD-1-failure patients: 2 confirmed responses (1 CR stage IV cervical, 1 PR stage IV gastro-esophageal), 9 stable disease.","No grade 4 treatment-emergent adverse events; two grade 3 immune-related AEs. Maximum tolerated dose not reached; DLT at 700 mg.","Durable disease control: uveal melanoma (>12 cycles), cutaneous melanoma (>14, >17 cycles), SCLC (>22 cycles).","Phase 2 monotherapy and in combination with PD-1 inhibitor is now underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-293959","json":"https://secwatch.observer/filing/0001193125-23-293959.json","markdown":"https://secwatch.observer/filing/0001193125-23-293959.md","text":"https://secwatch.observer/filing/0001193125-23-293959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312523293959/0001193125-23-293959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312523293959/d35885d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:35:57.059824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}